Artiva Biotherapeutics, Inc.
ARTV evidence brief
What we can confirm
- BioSniper Score:
- 10.0 / 10
- Market Cap:
- $499.7M
What it means
What to watch
Prepared research question
What matters most for ARTV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARTV
Artiva Biotherapeutics (ARTV) is a clinical-stage biotechnology company developing allogeneic NK-cell therapies, primarily AlloNK, for autoimmune diseases, with a lead indication in refractory rheumatoid arthritis.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$499.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Artiva Biotherapeutics (ARTV) is a clinical-stage biotechnology company developing allogeneic NK-cell therapies, primarily AlloNK, for autoimmune diseases, with a lead indication in refractory rheumatoid arthritis.
- Cash and equivalents of $301.5M as of 2026-06-30 [sec].
- Net income of -$25.0M as of 2026-06-30 [sec].
- Shareholders' equity of $347.5M as of 2026-06-30 [sec].
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA [news · published 2026-08-06].
- Initial Phase 2a data showed 71% ACR50 response in refractory RA patients with at least six months of follow-up [news · published 2026-05-08].
What works
- AlloNK received FDA RMAT designation for refractory RA, which may expedite development and review [news · published 2026-08-06].
- Initial clinical data demonstrated 71% ACR50 response in refractory RA with no relapses reported [news · published 2026-05-08].
- The company has a robust cash position of $301.5M as of 2026-06-30, providing runway for operations [sec].
- Over 100 patients have been treated with AlloNK across autoimmune and oncology indications, indicating broad clinical experience [news · published 2025-11-12].
What to weigh
- The company reported a net loss of -$25.0M as of 2026-06-30, indicating ongoing operating expenses exceed revenue [sec].
- AlloNK is still in clinical development with no approved products, so revenue generation is uncertain [news · published 2026-05-11].
- The Phase 3 registrational trial for refractory RA has not yet started, and pivotal data are pending [news · published 2026-08-06].
- Competition in the autoimmune cell therapy space is increasing, and AlloNK's long-term efficacy and safety remain unproven [news · published 2026-08-18].
From the filings
Quoted directly from source documents.
FDA RMAT designation for AlloNK plus rituximab
“U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA)”
News · August 6, 2026
71% ACR50 response in refractory RA
“Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up”
News · May 8, 2026
Catalyst timeline
- 2023-08-01 · Phase 2 start for AB-201 in HER2+ solid tumors — A multicenter, open-label Phase 1/2 trial evaluating AB-201 in advanced HER2+ solid tumors.
- 2024-04-03 · Phase 1 start for AB-101 in lupus nephritis — Phase 1 study of allogeneic NK-cell therapy AB-101 in combination with B-cell depleting mAb for lupus nephritis or refractory SLE.
- 2025-07-09 · Phase 2a start for AlloNK in rheumatologic diseases — Open-label Phase 2a study of AlloNK plus rituximab in relapsing B-cell dependent rheumatologic diseases.
Risks & what to watch (4)›
Key risks
- No approved products — AlloNK is still in clinical trials; no revenue from product sales yet [news · published 2026-05-11].
- Net loss reported — Net loss of -$25.0M as of 2026-06-30 indicates ongoing cash burn [sec].
- Phase 3 trial pending — Phase 3 registrational trial for refractory RA has not yet started; pivotal data are needed [news · published 2026-08-06].
- Competitive landscape — Increasing competition in autoimmune cell therapy; AlloNK's long-term profile unproven [news · published 2026-08-18].
What to watch
- Updated clinical data from the Phase 2a basket trial for AlloNK in refractory RA, expected in H2 2026 [news · published 2026-09-08].
- Initiation of the Phase 3 registrational trial for AlloNK in refractory RA, expected in 2026 [news · published 2026-05-11].
- FDA interaction to discuss potential pivotal trial design for AlloNK, expected in H1 2026 [news · published 2026-03-10].
- Updated clinical data for AlloNK in Sjögren disease, expected in H2 2026 [news · published 2026-09-08].
Sources: Catalysts · News · Generated October 5, 2026 · How we verify sources →
Run Artiva Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Artiva Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
21 buys · 12 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$19.7M
| Holder | Shares | Value |
|---|---|---|
| 5am venture management, llc | 2,353,304 | $15.2M |
| vanguard capital management llc | 207,686 | $1.3M |
| wellington management group llp | 194,108 | $1.3M |
| millennium management llc | 123,270 | $794K |
| jane street group, llc | 39,496 | $254K |
| bridgeway capital management, llc | 35,000 | $225K |
| vanguard fiduciary trust co | 32,810 | $211K |
| simplify asset management inc. | 23,230 | $150K |
| sanctuary advisors, llc | 21,581 | $139K |
| northern trust corp | 12,208 | $79K |
Showing top 10 of 13 institutional holders of Artiva Biotherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 0.8
- Shares short
- 148,487
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARTV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics (ARTV) is a clinical-stage biotechnology company developing allogeneic NK-cell therapies, primarily AlloNK, for autoimmune diseases, with a lead indication in refractory rheumatoid arthritis.
Who is the CEO of Artiva Biotherapeutics, Inc.?
Dr. Fred Aslan M.D. is the chief executive officer of Artiva Biotherapeutics, Inc. (ARTV).
Where is Artiva Biotherapeutics, Inc. headquartered?
Artiva Biotherapeutics, Inc. (ARTV) is headquartered in San Diego, CA, United States.
What therapeutic areas does Artiva Biotherapeutics, Inc. focus on?
Artiva Biotherapeutics, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.